Running title: Kiss1r (Gpr54) heterozygosity delays breast cancer progression PRECIS: Using a knockout model for the pro-metastatic receptor Kiss1R, this study established its role and signaling functions in initiation as well as progression in well-established models of breast cancer.
Introduction
KISS1 receptor (KISS1R, also named GPR54) coupled to its endogenous ligands, kisspeptins (KISS1 gene product), has been revealed to play a pivotal role for the onset of puberty and to suppress cancer metastasis (1) (2) (3) (4) (5) (6) (7) . Kisspeptins regulate cell proliferation, migration, and invasion in different cell lines via KISS1 receptor/GPR54 (8) (9) (10) . In pubertal development, mouse Kiss1 was revealed as a phenocopy of Kiss1r, since in knockout mouse models where Kiss1 or Kiss1r was deleted, similar phenotypes were observed in both Kiss1 and Kiss1r knockout mice (1, 3, 11) . In cancer, various experimental and clinical studies have shown that kisspeptins could suppress cancer metastasis (12) . We recently found that genes located at chromosome 6q21-32, which was often lost in metastatic breast cancer and melanoma, regulated KISS1 gene at chromosome 1q32 (9, 13) . Notably, genomic studies have revealed a gain of chromosome 1q32 in primary breast cancer and loss of chromosome 6q21-32 in aggressive breast cancer (14) (15) (16) (17) (18) (19) (20) (21) . Those genomic studies with recent findings suggest that KISS1 and KISS1R expression may be increased at the early stage of tumor development. Earlier studies focused on KISS1 function in cancer metastasis on the basis of KISS1 loss in metastatic cancer, and revealed a role of kisspeptin-activated KISS1R signaling (hereafter, KISS1/KISS1R signaling) for metastasis suppression. However, a role of endogenous KISS1/KISS1R signaling in early stages of cancer progression is still unclear, while it has been shown that the expression of KISS1 and KISS1R was higher in non-aggressive cancer than in normal and/or metastatic cancer (9, 13, (22) (23) (24) .
MMTV (mouse mammary tumor virus)-PyMT (polyoma virus middle T antigen) mouse
model is widely used to investigate a relationship between human and mouse breast cancer development and metastasis (25, 26) . The MMTV-PyMT mouse model is time-saving for investigating tumor progression, since PyMT-induced hyperplasia is usually detected as early as the onset of puberty at 3 weeks and aggressive carcinoma with lung metastasis is found at 11 weeks (25, 26) . An absence of mammary gland development in Kiss1-or Kiss1r-deficient female Author Manuscript Published OnlineFirst on August 18, 2011; DOI: 10.1158/0008-5472. mice was closely linked to the absence of central Kiss1/Kiss1r signaling for the onset of puberty (1, 3, 11) . However, the heterozygous mice for Kiss1 or Kiss1r did not cause any defects in pubertal development, including postnatal mammary gland development (1, 3, 11) , suggesting that Kiss1r heterozygous condition in MMTV-PyMT mouse could be a good model to understand breast-restricted Kiss1/Kiss1r signaling in the early stage of breast cancer development.
In this study, we found that Kiss1r heterozygosity delayed PyMT-induced breast cancer development and metastasis. Notably, Kiss1r heterozygosity (Kiss1r +/-) attenuated breast tumor initiation, tumor growth, latency, multiplicity and metastasis induced in MMTV-PyMT/Kiss1r mouse models. Kiss1 or Kiss1r silencing in pubertal breast epithelia confirmed that Kiss1/Kiss1r signaling in breast epithelial cells was necessary for breast hyperplasia. To limit any effect of endogenous hormones, we isolated mouse primary breast cancer cells from MMTVPyMT/Kiss1r +/+ and MMTV-PyMT/Kiss1r +/-mice and examined the tumorigenesis in vitro and in vivo. We found that Kiss1r heterozygosity (Kiss1r +/-) attenuated breast tumor growth when tumor cells were orthotopically injected into NOD.SCID/NCr mice. To understand the molecular mechanism of Kiss1r regulation of tumorigenesis, we further determined that dosage-dependent regulation of RhoA activity by KISS1R was critical for Ras-induced tumorigeneity. In summary, our study suggests that KISS1/KISS1R signaling regulates breast tumor initiation, progression, and metastasis by activating Gαq-p63RhoGEF-RhoA signaling pathway.
Materials and methods

Animal Studies
Transgenic FVB/N mice expressing the polyoma middle T antigen under the control of MMTV long terminal repeat promoter (MMTV-PyMT) were received from Dr. Jeffrey M. Rosen and Dr. Jianming Xu at Baylor College of Medicine (Houston, TX). All matings were performed with male mice heterozygous for the PyMT transgene and female C57BL/6 Kiss1r +/-mice received from Dr. Eric L. Gustafson at Schering-Plough Research Institute (Kenilworth, NJ).
Genotyping for the PyMT transgene was performed according to the protocol of Jackson Laboratories (Bar Harbor, ME). All mice analyzed in this study were virgin females. Animal protocols used for this study were approved by the IACUC, Texas A&M Health Science Center.
In vivo studies
Mice were observed three times a week for mammary tumors by eye examination and finger palpation. Tumor length (L) and width (W) were measured once a week by a caliper and tumor volume was estimated by the formula, (W 2 × L) / 2. Mice were euthanized at different stages of mammary tumorigenesis, and their mammary glands and tumors were collected for morphologic and biochemical analyses. For the whole-mount staining, the fourth inguinal mammary fat pads were excised, fixed with ethanol, and then stained with carmine alum. For histological study, tissues were formalin fixed for 24 hrs, and embedded in paraffin. Tissues were cut at 5μm in width, stained with hematoxylin and eosin, and evaluated by three different observers. Analyses and descriptions were followed in accordance with the guidelines in the NIH mammary gland pathology. Anti-Kiss1 and -Kiss1r antibodies from Santa Cruz Biotechnology (Santa Cruz, CA)
were used for the immunohistochemistry. 
In vitro studies
Primary tumor cells were isolated from the tumor mice and cultured in DMEM/F12 medium supplemented with 5% horse serum, 1% streptomycin/penicillin, 20ng/ml EGF, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10ȝg/ml insulin at first day, and then in DMEM medium.
To examine cell proliferation, cells were manually counted every day until 12 days. In order to examine cell migration, Boyden chamber assays were used. For colony formation assays, cells were cultured in 0.35% soft agar for 2 weeks and then colonies were stained with crystal violet.
MCF10A cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM/F12 medium supplemented with 5% horse serum, 1% streptomycin/penicillin, 20ng/ml EGF, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10ȝg/ml insulin. For RNA quantification, real-time PCR analyses were performed using SYBR green reagents in Prism 7300 real-time PCR machine (Applied Biosystems, Foster City, CA), and ¨¨Ct values were calculated. Gapdh as a reference was used for normalization. Anti-KiSS1, KiSS1R, RhoA, Cdc42, Rac1, Ras, and Actin antibodies were used for the Western blot (Santa Cruz Biotechnology, Santa Cruz, CA). For the Rho GTPases activity was performed using pulldown assays with GST-PAK PBD or GST-Rhotekin RBD, respectively. To detect active Rho GTPases, the appropriate antibody was used. For the luciferase assay, luciferase assay kit was used according to the manufacture's protocol (Promega, Madison, MI). Cells were transfected with pSRF-luc or pSRE-luc for 6hrs to 24hrs and then subjected to the luciferase activity. 
Results
Kiss1r heterozygosity delays mouse breast tumor development and lung metastasis
To investigate the roles of Kiss1 receptor (Kiss1r) in breast tumor development and metastasis in vivo, we generated the MMTV-PyMT/Kiss1r mouse models. As described in the materials and methods section, we obtained PyMT/Kiss1r wild type (PyMT/Kiss1r mice, 50% of mice developed tumors in 11 weeks compared to 7 weeks in PyMT/Kiss1r +/+ mice (P < .0001), whereas PyMT/Kiss1r -/-mice generated no palpable tumor (Fig.1A) . Thus, our data indicated that Kiss1r heterozygosity affected tumor latency and Kiss1r might be essential for breast tumor development.
Meanwhile, pubertal phenotypes such as vaginal opening at the precise time schedule showed no differences between PyMT/Kiss1r +/+ and PyMT/Kiss1r +/-mice, which was consistent with previous reports that Kiss1r (as well as Kiss1) heterozygous condition did not significantly alter the level of sexual hormones and not affect pubertal development (1, 11) . Lack of tumor development in PyMT/Kiss1r -/-mice suggests that hypothalamic Kiss1/Kiss1r signaling regulates postnatal mammary development, which is consistent with previous findings that Kiss1r knockout mice did not have postnatal mammary gland development and that PyMT-induced tumors arose at the time of pubertal mammary gland development (1, 11, 26) . Altogether, Kiss1r heterozygosity resulted in the haploinsufficiency for PyMT-induced mammary tumor development, which was not due to the pubertal defect of mammary gland development. 1C ; n = 10 per group, P = .029). Therefore, our data indicated that Kiss1r haploinsufficiency attenuated breast tumor latency and multiplicity, and further affected tumor growth.
PyMT-induced breast tumors primarily metastasize to lung, which is normally detected at 11
weeks of age (25, 26) . To investigate whether Kiss1r heterozygosity affected breast tumor metastatic growth at lung, we prepared lung tissue sections and counted metastatic tumor foci in
PyMT/Kiss1r +/+ and PyMT/Kiss1r +/-mice. At 11 weeks of age, the number of tumor foci found in PyMT/Kiss1r +/+ lung was significantly higher than that in PyMT/Kiss1r +/-lung ( Fig. 1D ; n = 10 per group, P < .0001). Thus, our data indicated that Kiss1r haploinsufficiency further affected breast tumor lung metastasis.
Kiss1r heterozygosity delays the incidence of mouse breast hyperplasia, tumor formation, and malignancy
As Kiss1r heterozygosity affected tumor latency, multiplicity and growth, we next examined whether those results were due to a delay of tumor incidence. To analyze mammary tumor incidence, we prepared whole-mounting analysis on the fourth inguinal mammary fat pads at the age of 5 to 9 weeks since whole mounting preparations were preferred to address premalignant lesions of mammary glands, termed mammary intraepithelial neoplasia (MIN) or hyperplastic atypia that results in mammary tumors. When hyperplastic nodules in the 4 th inguinal mammary fat pads of PyMT/Kiss1r +/+ (n = 20), PyMT/Kiss1r +/-(n = 21) and PyMT/Kiss1r -/-(n = 11) mice at ages from 5 to 9 weeks were counted, respectively, we found that the total number of hyperplastic 2C ; P = 0.0213). Thus, our data indicated that Kiss1r heterozygosity delayed tumor malignancy and progression.
We next examined an expression of Kiss1r in tumor tissues using the immunohistochemistry.
Compared to PyMT/Kiss1r +/-tumor, PyMT/Kiss1r +/+ tumor expressed higher Kiss1r (Fig. 2D ).
Although Kiss1r was detected in fibroblast and endothelium, both Kiss1 and Kiss1r were found in luminal epithelial tumor cells (Fig. 2D) , suggesting autocrine Kiss1/Kiss1r signaling. Autocrine Kiss1/Kiss1r signaling is sufficient for mouse breast tumor initiation
To investigate a local function of Kiss1/Kiss1r signaling for hyperplasia, lentiviruses for shRNAs specific for Kiss1 and Kiss1r were injected into 4 th nipples at 2 weeks of age prior to pubertal mammary development. Mice were sacrificed at 5 weeks of age when hyperplasia was developed. Lentiviral knockdown strategies repressed the expression levels of either Kiss1 or Kiss1r in breast epithelia (Fig. 3A and B) . Compared to the silencing with control shRNA (scr), both Kiss1 and Kiss1r silencing in breast epithelia caused a significant decrease of hyperplastic nodule number ( (Fig. 4A) . On the other hand, no significant alteration of Kiss1 expression was detected (Fig. 4A) 
Kiss1r sufficiently regulates tumorigeneity via RhoA
To understand the molecular mechanisms of Kiss1r signaling in the regulation of tumorigeneity, we next examined the activation of Rho GTPases in breast tumor cells since Rho GTPases are reported to regulate tumor progression and metastasis (27, 28) . In PyMT/Kiss1r +/+ primary tumor cells, knockdown of Kiss1r expression significantly decreased RhoA activity in a dose-dependent manner but did not affect the activity of either Cdc42 or Rac1 (Fig. 5A ). RhoA activity in PyMT/Kiss1r +/-tumor cells was also decreased when compared to that in PyMT/Kiss1r +/+ tumor cells (Fig. 5A) To confirm the roles of human KISS1R for tumorigeneity in human breast epithelium, we transformed MCF10A human normal breast epithelial cells by overexpressing the constitutively active H-Ras (H-Ras V12 ) to induce tumorigenesis, as PyMT-induced tumorigenesis was known to require oncogenic activation of Ras (29, 30) . As shown in figure 5C , overexpression of the active H-Ras V12 transformed the MCF10A breast epithelial cells and induced anchorage-independent colony growth on soft agar. Knockdown of KISS1R using specific shRNA for human KISS1R
reduced Ras-induced anchorage-independent colony formation by approximately 37% ( = 7, KISS1R shRNA vs. scr shRNA, P = .0002), suggesting that human KISS1R plays a key role in Ras-induced MCF10A cell tumorigenesis. We further examined whether KISS1R-mediated RhoA activation was involved in Ras-induced tumorigenesis using the anchorage-independent colony growth assays. Inactive mutant of RhoA (RhoA DN) decreased Ras-induced colony formation of MCF10A ( Fig. 5D ; n = 7, RhoA DN vs. control, P < .0001). In addition, RhoA inhibitor (Y27632) blocked Ras-induced tumorigenesis in MCF10A cells that express RhoA, indicating that Ras-induced tumorigenesis requires RhoA activation ( Fig. 5D ; n = 7, RhoA inhibitor vs. control, P = .0001). On the other hand, dominant active form of RhoA (RhoA DA) recovered the inhibitory effect of KISS1R deficiency (knockdown) in Ras-induced tumorigenesis (n = 7, RhoA DA + KiSS1R shRNA vs. KiSS1R shRNA, P = .0097), suggesting that RhoA is the key downstream target of KISS1R in Ras-induced MCF10A cell tumorigenesis. Together, our data indicate that KISS1R-mediated RhoA activation is important for Ras-induced tumorigenesis, similar to our results found in the PyMT/Kiss1r mouse tumor models.
Kisspeptin activates RhoA-mediated transcription through KISS1R-Gαq-p63RhoGEF
To delineate KISS1/KISS1R signaling to RhoA, we performed RhoA activity assays when cells were serum-starved for 24hr and then incubated for 6hr in the absence or presence of kisspeptin-10 (Kp10, 100nM). Kisspeptin-10 (100nM) increased GTP-bound RhoA in HEK293 cells overexpressing KISS1R (Fig. 6A) . Since serum response factor (SRF) transcriptional activity is widely used for the readout of RhoA GTPase activation (31-33), we performed the luciferase assays for SRF-dependent promoter activity as the readout of RhoA activation.
Kisspeptin-10 increased SRF-luciferase activity in cells transfected with KISS1R (Kisspeptin-10 in KiSS1R cells vs. none in KiSS1R cells, P = 0.0309) but not with empty vector (Fig. 6B) .
Consistently, kisspeptin-10 also activated serum response element (SRE)-luciferase activity via KISS1R (data not shown). Therefore, our data indicate that KISS1/KISS1R signaling directly activates RhoA. We next investigated whether KISS1/KISS1R signaling increases SRF transcriptional activity through RhoA activation. Dominant active form of RhoA (RhoA DA) highly increased SRF transcriptional activity in HEK293 cells stably expressing KISS1R (RhoA DA vs. empty, P = .0027). RhoA wild type (RhoA WT) has little effect on the basal SRF transcriptional activity (RhoA WT plus kisspeptin-10 vs. RhoA WT, P = .0002) (Fig. 6C, To understand how KISS1 receptor activates RhoA, we examined whether the activation of RhoA was mediated by Gαq, as it was revealed that KISS1R selectively coupled to Gαq upon kisspeptin stimulus (1, 4, 8, 34) . In HEK293 cells stably transfected with KISS1R, kisspeptin-10 stimulation or constitutively active mutant of Gαq (Gαq CA) induced SRF transcriptional activity (Gαq CA vs. empty, P = .0015; Gαq WT plus kisspeptin-10 vs. Gαq WT, P = .0003), while Gαq wild type (Gαq WT) alone did not affect SRF transcriptional activity (Fig. 6C, 3 st , 4 nd , and 7 th bars). A dominant negative mutant of Gαq (Gαq DN) attenuated kisspeptin-10-induced SRF transcriptional activation (Fig. 6C , 5 rd and 6 th bars). Thus, our data suggest that the activation of RhoA by kisspeptin-10 is mediated by KiSS1R-Gαq signaling pathway.
As Gαq activates RhoA via p63RhoGEF (also called GEFT) (35-37), we further examined the Gαq coupling to p63RhoGEF. In KISS1R-overexpressing cells, p63RhoGEF wild type (p63RhoGEF WT) did not affect basal or kisspeptin-10-induced SRF transcriptional activity (p63RhoGEF WT plus kisspeptin-10 vs. p63RhoGEF WT, P =.0003), but catalytic domaindeleted mutant of p63RhoGEF (p63RhoGEF ǻN) inhibited kisspeptin-10 activation of SRF transcriptional activity (Fig. 6C, 8 th to 11 th bars). Furthermore, p63RhoGEF ǻN suppressed SRF transcriptional activation by Gαq CA (Fig. 6C, 12 th bar; Gαq CA vs. p63RhoGEF ǻN plus Gαq CA, P = .0001), indicating that p63RhoGEF is downstream of Gαq in the activation of KISS1R. 
We further examined whether KISS1/KISS1R signaling activated RhoA-dependent SRF transcriptional activity through Gαq-p63RhoGEF. RhoA DN inhibited Gαq CA-induced SRF transcriptional activation (Gαq CA vs. RhoA DN plus Gαq CA, P = .0001), and p63RhoGEF ǻN did not inhibit RhoA DA-increased SRF transcriptional activity (Fig. 6C, 18 th and 19 th bars).
Therefore, our data indicate that KiSS1/KiSS1R signaling activates Gαq-p63RhoGEF-RhoA signaling pathway.
Finally, we examined whether Kiss1r heterozygosity regulated RhoA-dependent gene expression in tumor progression using real-time PCR assays and MatInspector software (38) .
Among genes of which promoter region contained SRE, we found that the expression levels of
Vegf, ErbB2, c-fos, and Mmp-9 in PyMT/Kiss1r +/-tumor compared to that in PyMT/Kiss1r +/+ tumor was significantly reduced (Fig. 6D) , indicating that Kiss1r heterozygosity selectively affected RhoA-dependent expression level of key genes involved in cancer progression. 
Discussion
KISS1/KISS1R signaling has been implicated in cancer metastasis, which was first revealed in xenograft tumor growth and experimental metastasis models (4, 6) . However, its functional requirement in the early stages of cancer development was unclear. In this study, we demonstrated that mouse Kiss1r heterozygosity delayed breast cancer initiation, progression and metastasis in MMTV-PyMT mouse model system. In our PyMT/Kiss1r mouse models, Kiss1r heterozygosity (PyMT/Kiss1r +/-) diminished hyperplasia, resulting in the delay of tumor formation, progression, and lung metastasis. Furthermore, we confirmed that knockdown of Kiss1 and Kiss1r locally inhibited mammary gland hyperplasia and that the dosage-dependent regulation of breast tumor initiation by Kiss1r was connected to RhoA activity. Accordingly, we demonstrate that KISS1/KISS1R signaling regulates early steps of tumor development through
RhoA activation by coupling to Gαq-p63RhoGEF.
In xenograft mouse tumor model systems, KISS1 overexpression blocked cancer metastases without affecting tumorigenesis (4, 6, 7) . However, xenograft mouse tumor model has limitations to understand KISS1/KISS1R signaling in early stages of tumor progression since it is not able to recapitulate some aspects of tumorigenesis (25) . showed that KISS1/KISS1R signaling seems to be required for tumor cell growth and motility, as knockdown of KISS1 or KISS1R as well as Kiss1r heterozygosity reduced cell growth and motility. Therefore, KISS1/KISS1R signaling may form a fine-tuned network in the cells and during tumor progression.
Our study further identified that KISS1/KISS1R regulated breast tumorigenesis via the activation of RhoA by Gαq-p63RhoGEF signaling pathway. Somatic mutation of Gαq (GNAQ) at codon 209 was frequently found in uveal melanoma and blue naevi (39, 40) . Therefore, constitutively active mutation of Gαq seems to be involved in melanoma progression. Recent studies delineated that p63RhoGEF linked the activation of Gαq and RhoA (36, 37) . Our lab also revealed that p63RhoGEF overexpression induced NIH3T3 transformation (35) . RhoA upstream of Cdc42 and Rac1 in regulating dynamics of cell growth and motility is known to affect preneoplastic transformation in primary mammary epithelial cells (41) . Consistently, Ras 
